Literature DB >> 28975434

High-intensity focused ultrasound (HIFU) treatment for uterine fibroids: a meta-analysis.

Yongshuo Ji1, Kaimeng Hu2, Yu Zhang1, Lijun Gu3, Junqiu Zhu1, Linglin Zhu1, Yanfei Zhu1, Hong Zhao4.   

Abstract

PURPOSE: High-intensity focused ultrasound (HIFU) is a non-invasive uterine-preserving treatment alternative to hysterectomy for women with fibroids.
METHODS: We performed this meta-analysis to evaluate the efficacy of HIFU in the treatment of women with symptomatic fibroids comparing it to other approaches including medical treatment with mifepristone (Mife), traditional surgery with myomectomy or hysterectomy (MYC/HRM), and radiofrequency ablation (RF). 16 studies with 1725 women were included.
RESULTS: The pooled data of HIFU comparing it to other methods in terms of complete or partial response rate (CR/PR) was not significantly better, but in subgroup analysis, the response rate was significantly higher than Mife, significantly lower than RF and comparable to MYC/HRM, respectively. For the endpoints of safety, the superiority of HIFU compared to MYC/HMR or Mife was found to be significant in terms of pain/discomfort, fever, transfusion, genital tract, gastrointestinal tract, and anesthesia-related complications, while no superiority was identified for skin burn, urinary tract, and nervous system complications.
CONCLUSION: These results suggest that HIFU treatment of uterine leiomyomas leads to clinical improvement with few significant clinical complications and adverse events.

Entities:  

Keywords:  HIFU; Hysterectomy; Mifepristone; Myomectomy; Radiofrequency ablation; Uterine fibroids

Mesh:

Year:  2017        PMID: 28975434     DOI: 10.1007/s00404-017-4548-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  Multidisciplinary management to optimize outcome of ultrasound-guided high-intensity focused ultrasound (HIFU) in patients with uterine fibroids.

Authors:  Florian Recker; Marcus Thudium; Rupert Conrad; Milka Marinova; Holger Strunk; Tolga Tonguc; Sara Dohmen; Guido Luechters; Birgit Bette; Simone Welz; Babak Salam; Kai Wilhelm; Eva K Egger; Ullrich Wüllner; Ulrike Attenberger; Alexander Mustea
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

2.  Prediction of Clinical Outcome for High-Intensity Focused Ultrasound Ablation of Uterine Leiomyomas Using Multiparametric MRI Radiomics-Based Machine Leaning Model.

Authors:  Yineng Zheng; Liping Chen; Mengqi Liu; Jiahui Wu; Renqiang Yu; Fajin Lv
Journal:  Front Oncol       Date:  2021-09-10       Impact factor: 6.244

3.  The Comparison of Life Quality between Ultrasound-Guided High-Intensity Focused Ultrasound and Laparoscopic Myomectomy for the Treatment of Uterine Fibroids.

Authors:  Bilin Yuan; Xinyi Qin; Jie Xi
Journal:  Comput Math Methods Med       Date:  2022-08-05       Impact factor: 2.809

Review 4.  Focused Ultrasound (FUS) for Chronic Pain Management: Approved and Potential Applications.

Authors:  Lazzaro di Biase; Emma Falato; Maria Letizia Caminiti; Pasquale Maria Pecoraro; Flavia Narducci; Vincenzo Di Lazzaro
Journal:  Neurol Res Int       Date:  2021-06-29

5.  Wedged gel pad for bowel manipulation during MR-guided high-intensity focused ultrasound therapy to treat uterine fibroids: a case report.

Authors:  Teija Sainio; Gaber Komar; Jani Saunavaara; Visa Suomi; Kirsi Joronen; Antti Perheentupa; Antti Viitala; Roberto Blanco Sequeiros
Journal:  J Ther Ultrasound       Date:  2018-11-28

6.  Transrectal high-intensity focused ultrasound (HIFU) for management of rectosigmoid deep infiltrating endometriosis: results of Phase-I clinical trial.

Authors:  C-A Philip; S Warembourg; M Dairien; C Lefevre; A Gelet; F Chavrier; N Guillen; H Tonoli; E Maissiat; C Lafon; G Dubernard
Journal:  Ultrasound Obstet Gynecol       Date:  2020-09       Impact factor: 7.299

7.  Effectiveness and safety of focused ultrasound ablation surgery compared with radiofrequency ablation in primary hepatocellular carcinoma treatment: a meta-analysis.

Authors:  Jian-Ying Zhang; Long Chen; Rong Ma; Chun-Mu Miao; Yun-Bing Wang
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.